Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

913 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Etanercept for the treatment of rheumatoid arthritis.
Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Lethaby A, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD004525. doi: 10.1002/14651858.CD004525.pub2. Cochrane Database Syst Rev. 2013. PMID: 23728649 Review.
Cyclosporine in rheumatoid arthritis: documented efficacy and safety.
Tugwell P. Tugwell P. Semin Arthritis Rheum. 1992 Jun;21(6 Suppl 3):30-8. doi: 10.1016/0049-0172(92)90011-2. Semin Arthritis Rheum. 1992. PMID: 1502565 Review.
Cyclosporin in the treatment of rheumatoid arthritis.
Tugwell P. Tugwell P. J Autoimmun. 1992 Apr;5 Suppl A:231-40. doi: 10.1016/0896-8411(92)90038-r. J Autoimmun. 1992. PMID: 1503615 Review. No abstract available.
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.
Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, Chalmers A, Esdaile JM, Klinkhoff AV, Kraag GR, et al. Tugwell P, et al. Lancet. 1990 May 5;335(8697):1051-5. doi: 10.1016/0140-6736(90)92630-z. Lancet. 1990. PMID: 1970370 Clinical Trial.
Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires.
Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace E, Bennett KJ, Williams HJ, Egger M, Alarcon GS, Guttadauria M, et al. Tugwell P, et al. Arch Intern Med. 1990 Jan;150(1):59-62. doi: 10.1001/archinte.150.1.59. Arch Intern Med. 1990. PMID: 2404483 Clinical Trial.
Meta-analysis of injectable gold in rheumatoid arthritis.
Clark P, Tugwell P, Bennett K, Bombardier C. Clark P, et al. J Rheumatol. 1989 Apr;16(4):442-7. J Rheumatol. 1989. PMID: 2664167 Clinical Trial.
The change in percentage in favor of gold (adjusted for placebo) was as follows: active joint count 30.1%, (p less than 0.00001), grip strength 13.7% (p less than 0.013), functional capacity 13% (p less than 0.0005), hemoglobin concentration 5.3% (p le …
The change in percentage in favor of gold (adjusted for placebo) was as follows: active joint count 30.1%, (p less than 0.00001), gri …
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis.
Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. Tugwell P, et al. J Rheumatol. 1987 Jun;14(3):446-51. J Rheumatol. 1987. PMID: 3305931 Clinical Trial.
913 results
Jump to page
Feedback